![]() |
Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol. 2017;23(4):323-330. Published online 2017 Sep 5 DOI: https://doi.org/10.3350/cmh.2017.0005
|
Citations to this article as recorded by
Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment
Zhong-Bin Li, Dan-Dan Chen, Yun-Fei Jia, Qing-Juan He, Li Cui, Feng-Xia Du, Yao-Jie Kang, Xin Feng, Mengwen He, Xue-Yuan Jin, Jing Chen, Yudong Wang, Dong Ji, George Lau, Shu-Gao Wu
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef Risk factors of low‐level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study
He Chen, Juan‐Juan Fu, Li Li, Xia Wang, Xiu‐Cheng Pan
Journal of Gastroenterology and Hepatology.2024; 39(1): 180. CrossRef A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
Sheila F. Lumley, Marion Delphin, Jolynne F. Mokaya, Cedric C.S. Tan, Emily Martyn, Motswedi Anderson, Ka Chun Li, Elizabeth Waddilove, Gloria Sukali, Louise O. Downs, Khadija Said, Dorcas Okanda, Cori Campbell, Eli Harriss, Yusuke Shimakawa, Philippa C.
Journal of Clinical Virology.2024; 174: 105711. CrossRef The urgency to expand the antiviral indications of general chronic hepatitis B patients
Ping Fan, Lan-Qing Li, En-Qiang Chen
Frontiers in Medicine.2023;[Epub] CrossRef Research Progress of Low-Level Viraemia in Patients with Chronic Hepatitis B
祥运 张
Advances in Clinical Medicine.2023; 13(12): 20083. CrossRef The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years
Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei
Infection, Genetics and Evolution.2021; 89: 104706. CrossRef Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR
Jingjing Liang, Xinmiao Liang, Hong Ma, Leng Nie, Ying Tian, Guang Chen, Yu Wang
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews
Wellcome Open Research.2020; 5: 151. CrossRef Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
Hans L. Tillmann, Gbeminiyi Samuel
Expert Opinion on Pharmacotherapy.2019; 20(7): 873. CrossRef Entecavir
Reactions Weekly.2018; 1688(1): 98. CrossRef Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
Joon Yeul Nam, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2017; 23(4): 311. CrossRef
|